Abstract
Two hundred seventy-one consecutive patients treated from 1976 through 1986 were reviewed to estimate long-term survival. Disease-free survival for the entire cohort was 77% at five years and 74% at ten years. Humeral lesions had the best probability of survival (84% at ten years), followed by tibial lesions (81%) and femoral lesions (67%). Histologic response to preoperative chemotherapy was the strongest predictor of outcome. Those with little response had a survival estimate of 54% at ten years as compared to 68% for partial responders and approximately 90% for complete responders. Local recurrence was seen in 6.6% and was associated with an adverse effect on survival. Only two of the 18 patients with local recurrence have been rendered long-term disease-free survivors.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Amputation, Surgical / standards*
-
Amputation, Surgical / statistics & numerical data
-
Amputation, Surgical / trends
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bone Neoplasms / mortality
-
Bone Neoplasms / pathology
-
Bone Neoplasms / therapy*
-
Child
-
Child, Preschool
-
Clinical Protocols
-
Cohort Studies
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Dactinomycin / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Neoplasm Staging
-
New York City / epidemiology
-
Osteosarcoma / mortality
-
Osteosarcoma / pathology
-
Osteosarcoma / therapy*
-
Osteotomy / standards*
-
Osteotomy / statistics & numerical data
-
Postoperative Care / standards
-
Predictive Value of Tests
-
Preoperative Care / standards
-
Survival Analysis
-
Survival Rate
Substances
-
Bleomycin
-
Dactinomycin
-
Doxorubicin
-
Cyclophosphamide
-
Methotrexate